Engineering tumor-colonizing E. coli Nissle 1917 for detection and treatment of colorectal neoplasia
-
Published:2024-01-20
Issue:1
Volume:15
Page:
-
ISSN:2041-1723
-
Container-title:Nature Communications
-
language:en
-
Short-container-title:Nat Commun
Author:
Gurbatri Candice R., Radford Georgette A., Vrbanac Laura, Im JongwonORCID, Thomas Elaine M., Coker CourtneyORCID, Taylor Samuel R.ORCID, Jang YoungUk, Sivan Ayelet, Rhee KyuORCID, Saleh Anas A., Chien Tiffany, Zandkarimi FereshtehORCID, Lia Ioana, Lannagan Tamsin R. M., Wang TongtongORCID, Wright Josephine A., Kobayashi HirokiORCID, Ng Jia Q., Lawrence Matt, Sammour Tarik, Thomas Michelle, Lewis Mark, Papanicolas Lito, Perry Joanne, Fitzsimmons Tracy, Kaazan Patricia, Lim AmandaORCID, Stavropoulos Alexandra M., Gouskos Dion A., Marker Julie, Ostroff CheriORCID, Rogers Geraint, Arpaia NicholasORCID, Worthley Daniel L.ORCID, Woods Susan L.ORCID, Danino TalORCID
Abstract
AbstractBioengineered probiotics enable new opportunities to improve colorectal cancer (CRC) screening, prevention and treatment. Here, first, we demonstrate selective colonization of colorectal adenomas after oral delivery of probiotic E. coli Nissle 1917 (EcN) to a genetically-engineered murine model of CRC predisposition and orthotopic models of CRC. We next undertake an interventional, double-blind, dual-centre, prospective clinical trial, in which CRC patients take either placebo or EcN for two weeks prior to resection of neoplastic and adjacent normal colorectal tissue (ACTRN12619000210178). We detect enrichment of EcN in tumor samples over normal tissue from probiotic-treated patients (primary outcome of the trial). Next, we develop early CRC intervention strategies. To detect lesions, we engineer EcN to produce a small molecule, salicylate. Oral delivery of this strain results in increased levels of salicylate in the urine of adenoma-bearing mice, in comparison to healthy controls. To assess therapeutic potential, we engineer EcN to locally release a cytokine, GM-CSF, and blocking nanobodies against PD-L1 and CTLA-4 at the neoplastic site, and demonstrate that oral delivery of this strain reduces adenoma burden by ~50%. Together, these results support the use of EcN as an orally-deliverable platform to detect disease and treat CRC through the production of screening and therapeutic molecules.
Funder
U.S. Department of Health & Human Services | National Institutes of Health
Publisher
Springer Science and Business Media LLC
Subject
General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry,Multidisciplinary
Reference68 articles.
1. Mazzolini, R. et al. Engineered live bacteria suppress Pseudomonas aeruginosa infection in mouse lung and dissolve endotracheal-tube biofilms. Nat. Biotechnol. 41, 1089–1098 (2023). 2. Russell, B. J. et al. Intestinal transgene delivery with native E. coli chassis allows persistent physiological changes. Cell 185, 3263–3277. e3215 (2022). 3. Whitfill, T. & Oh, J. Recoding the metagenome: microbiome engineering in situ. Curr. Opin. Microbiol. 50, 28–34 (2019). 4. Forbes, N. S. Engineering the perfect (bacterial) cancer therapy. Nat. Rev. Cancer 10, 785–794 (2010). 5. Chien, T., Doshi, A. & Danino, T. Advances in bacterial cancer therapies using synthetic biology. Curr. Opin. Syst. Biol. 5, 1–8 (2017).
|
|